NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support **03 Mar 2015**

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.*

Important notices

- **Request for Information (RFI): An Internet Resource for Placental Research - Placental Atlas Tool (NOT-HD-15-005)**

1. Title: One-Year Administrative Supplements to NIMH-supported Research for FY2015 (Admin Supp)

Letter of Intent due date: N/A **Hyperlink:** (PA-15-128) **Type:**

Application Due Date: June 1, by 5:00 PM local time of applicant organization.

Purpose: The National Institute of Mental Health announces the availability of one-year administrative supplements to support on-going NIMH-supported research. Investigators with active NIMH-supported research grants can request supplemental funding in FY2015 for continued research in one of the NIMH identified priority areas. NIMH has identified specific areas of interest in accordance with its goal of accelerating mental health research as described in the Institute's Strategic Plan.

Budget: Application budgets are not limited but must reflect the actual needs of the proposed project. The project and budget periods must be within the currently approved project period for the existing parent award. Budgets are limited to one-year funds to be award in FY2015.

2. Title: Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research

Letter of Intent due date: N/A **Hyperlink:** (PA-15-127) **Type:** RO1

Application Due Date: June 5, Oct 5 2015 by 5:00 PM local time of applicant organization.

Purpose: The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

3. Title: Early-life Factors and Cancer Development Later in Life

Letter of Intent due date: N/A **Hyperlink:** (PA-15-126) **Type:** RO1
(PA-15-125) R21

Application Due Date: June 5, Oct 5 2015, by 5:00 PM local time of applicant organization

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Budget: RO1: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year

4. Title: **Administrative Supplements for Common Basic Sociobehavioral Mechanisms and Processes that Facilitate or Impede Self-Management of Chronic Conditions (Admin Supp)**

Letter of Intent due date: N/A **Hyperlink:** (PA-15-122) **Type:**

Application Due Date: May 5, 2015 by 5:00 PM local time of applicant organization.

Purpose: NIH's Basic Behavioral & Social Science Opportunity Network (OppNet) announces the opportunity of funds to support increases in costs on existing projects in order to elucidate basic mechanisms and processes that facilitate and/or impede an individual's attitudes, beliefs, knowledge, and behaviors involved with the self-management of chronic disease conditions within respective social and/or physical environment(s).

Budget: Direct costs are limited to $100,000 each year. Application budgets must reflect the actual needs of the proposed project. The project and budget periods must be within the currently approved project period for the existing parent award.

5. Title: **Developing Paradigm-Shifting Innovations for in vivo Human Placental Assessment in Response to Environmental Influences**

Letter of Intent due date: May 1, 2015 **Hyperlink:** **Type:**

Application Due Date: June 1, 2015, by 5:00 PM local time of applicant organization.

Purpose: This funding opportunity announcement (FOA) in support of the Human Placenta Project (HPP) aims to support the initial stages of development of entirely new or next-generation placental imaging and assessment technologies and methods that will increase our capability to assess human placental structure and function safely in vivo throughout gestation and to explore the impact of environmental influences on placental structure and function across pregnancy.

Budget: Applicants may request up to $3 million in direct costs plus applicable Facilities & Administrative (F&A) for the entire project period of up to 4 years. Note when a consortium is involved, the $3 million direct cost limit is exclusive of consortium F&A costs. These can be requested in addition to the $3 million direct costs limit. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

6. Title: **Minor Use Minor Species Development of Drugs**

Letter of Intent due date: June 19, 2015; November 20, 2015; June 17, 2016; November 18, 2016; June 16, 2017; November 17, 2017. **Hyperlink:** **Type:** RO1

Application Due Date: August 14, 2015; January 15, 2016; August 12, 2016; January 13, 2017; August 11, 2017; January 12, 2018, by 11:59 PM Eastern Time.

Purpose: This Funding Opportunity Announcement (FOA) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop, or support the development of new animal drugs intended for minor use in major species or intended for use in minor species.

- The FDA is authorized to provide grants only to assist in defraying the costs of qualified safety and effectiveness testing when a grant will either result in or substantially contribute to FDA approval or conditional approval of a new animal drug.
- Only companies developing drugs for veterinary use or parties working as research partners with such companies are eligible for grants.
- Only studies in support of new animal drugs that such companies have had designated for specified intended uses by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS), in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516, are eligible for grants.
- Qualified studies eligible for funding include those intended to support target animal safety or effectiveness, environmental safety, or human food safety.
- The protocol for a proposed study must be accepted by FDA/CVM's Office of New Animal Drug Evaluation (ONADE) prior to application submission.
- In addition to studies intended to directly establish target animal safety or effectiveness, the following manufacturing studies supportive of target animal safety or effectiveness are eligible for funding, provided a protocol has been accepted by FDA/CVM/ONADE: ◦A study to evaluate the stability of a MUMS drug
  - A study to validate analytical methods associated with the manufacture of a MUMS drug
  - A study to determine the homogeneity/segregation of an animal feed bearing or containing a MUMS drug
  - A study to validate analytical methods for an animal feed bearing or containing a MUMS drug.
- In addition to studies intended to directly establish human food safety, a separate study to validate an analytical method prior to the conduct of an in-life human food safety study is eligible for funding, provided a protocol has been accepted by FDA/CVM/ONADE.
- Applicants must include an explanation of how the proposed study will contribute to FDA approval or conditional approval of the product in the application's "Significance" section of the Research Strategy (PHS 398 Research Plan).

All funded studies are subject to the requirements of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 331 et seq.), regulations issued under it, and applicable Department of Health and Human Services (HHS) statutes and regulations.

Budget: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Brief definitions of some NIH grant mechanisms: **comprehensive list of extramural grant and cooperative agreement activity codes**

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

UH2/UH3 - Phase Innovation Awards Cooperative Agreement: Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete Glossary and acronym list of NIH Terms

NIH National Institutes of Health
Turning Discovery Into Health

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa de Vries*** • Tel: 9838 • Email: cdevries@sun.ac.za